MX337464B - Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer. - Google Patents

Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer.

Info

Publication number
MX337464B
MX337464B MX2013014395A MX2013014395A MX337464B MX 337464 B MX337464 B MX 337464B MX 2013014395 A MX2013014395 A MX 2013014395A MX 2013014395 A MX2013014395 A MX 2013014395A MX 337464 B MX337464 B MX 337464B
Authority
MX
Mexico
Prior art keywords
cancer chemotherapeutic
chemotherapeutic agents
acid
labile lipophilic
lipophilic prodrugs
Prior art date
Application number
MX2013014395A
Other languages
English (en)
Other versions
MX2013014395A (es
Inventor
James D Mcchesney
John T Henri
Sylesh Kumar Venkataraman
Mahesh Kumar Gundluru
Original Assignee
Arbor Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Therapeutics Llc filed Critical Arbor Therapeutics Llc
Publication of MX2013014395A publication Critical patent/MX2013014395A/es
Publication of MX337464B publication Critical patent/MX337464B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente solicitud describe un conjugado molecular lipofílico lábil al ácido de los agentes quimioterapéuticos anticáncer y los métodos para reducir o sustancialmente eliminar los efectos secundarios de la quimioterapia asociada con la administración de un agente quimioterapéutico anticáncer a un paciente en necesidad del mismo.
MX2013014395A 2011-06-06 2012-06-05 Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer. MX337464B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161493827P 2011-06-06 2011-06-06
US201161496367P 2011-06-13 2011-06-13
PCT/US2012/040930 WO2013002969A1 (en) 2011-06-06 2012-06-05 Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents

Publications (2)

Publication Number Publication Date
MX2013014395A MX2013014395A (es) 2015-01-16
MX337464B true MX337464B (es) 2016-03-07

Family

ID=47262153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014395A MX337464B (es) 2011-06-06 2012-06-05 Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer.

Country Status (10)

Country Link
US (6) US8440714B2 (es)
EP (1) EP2717699B1 (es)
JP (1) JP5621071B2 (es)
KR (1) KR101444693B1 (es)
CN (1) CN103763928B (es)
AU (1) AU2012275953B2 (es)
CA (1) CA2836914C (es)
MX (1) MX337464B (es)
SG (1) SG195018A1 (es)
WO (1) WO2013002969A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101444693B1 (ko) 2011-06-06 2014-09-26 아버 테라퓨틱스 엘엘씨 암 화학요법제의 산에 불안정한 친유성 전구약물
CA2922002A1 (en) * 2013-09-13 2015-03-19 Arbor Therapeutics, LLC Nanoparticulate compositions for targeted delivery of lipophilic drugs and acid labile, lipophilic prodrugs of cancer chemotherapeutics and their preparation
US10449210B2 (en) * 2014-02-13 2019-10-22 Ligand Pharmaceuticals Inc. Prodrug compounds and their uses
CN104529993B (zh) * 2014-12-12 2016-08-24 常州大学 一种含不饱和羰基的药物小分子的制备方法
US11826344B2 (en) 2015-11-19 2023-11-28 Howard University Composition, method of manufacture, and use of site-specific delivery of bruceolides for treatment of cancer and other diseases
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof
CN112300099A (zh) * 2019-08-02 2021-02-02 南开大学 药物的缩酮衍生物及其制备方法、药物组合物和用途
WO2022266135A1 (en) * 2021-06-16 2022-12-22 Veiled Therapeutics Llc Acid-labile chemotherapeutic paclitaxel based compounds for the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1998582A (en) * 1933-12-22 1935-04-23 Gunnar Larsen Whist Machine for twisting metal wires
JPS5829960B2 (ja) * 1980-02-07 1983-06-25 財団法人 微生物化学研究会 新規アントラサイクリン誘導体及びその製造法
ES2005031A6 (es) * 1987-10-13 1989-02-16 Uriach & Cia Sa J Procedimiento para la obtencion de 1,3-dioxolanos 2,4-disustituidos.
US5824701A (en) * 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
ATE171170T1 (de) * 1994-06-28 1998-10-15 Upjohn Co 7-äther-taxol ähnliche verbindungen antineoplastische verwendung und diese enthaltende pharmazeutische zusammenstellungen
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6191290B1 (en) 1999-02-24 2001-02-20 Uab Research Foundation Taxane derivatives for targeted therapy of cancer
KR20030096226A (ko) * 2000-10-13 2003-12-24 샤이어 바이오켐 인코포레이티드 개선된 세포간 전달을 보이는 디옥소란 동족체
US6825166B2 (en) * 2001-03-23 2004-11-30 Tapestry Pharmaceuticals, Inc. Molecular conjugates for use in treatment of cancer
PT1664033E (pt) * 2003-09-25 2008-01-17 Tapestry Pharmaceuticals Inc Análogos de 9,1o-a,a-oh-taxanos e processos para sua produção
WO2008106621A1 (en) 2007-02-28 2008-09-04 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US20080207743A1 (en) 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
CN101676291B (zh) * 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
SG194128A1 (en) * 2011-04-07 2013-11-29 Arbor Therapeutics Llc Taxane and abeo-taxane analogs
KR101444693B1 (ko) * 2011-06-06 2014-09-26 아버 테라퓨틱스 엘엘씨 암 화학요법제의 산에 불안정한 친유성 전구약물

Also Published As

Publication number Publication date
AU2012275953A1 (en) 2014-01-09
WO2013002969A1 (en) 2013-01-03
EP2717699A4 (en) 2014-10-08
KR101444693B1 (ko) 2014-09-26
US20180161439A1 (en) 2018-06-14
US20140249213A1 (en) 2014-09-04
NZ618596A (en) 2016-02-26
US10172957B2 (en) 2019-01-08
EP2717699B1 (en) 2020-06-03
KR20130138861A (ko) 2013-12-19
US20120309819A1 (en) 2012-12-06
CA2836914A1 (en) 2013-01-03
MX2013014395A (es) 2015-01-16
EP2717699A1 (en) 2014-04-16
SG195018A1 (en) 2013-12-30
CN103763928A (zh) 2014-04-30
US20130303601A1 (en) 2013-11-14
JP2014516076A (ja) 2014-07-07
CA2836914C (en) 2016-01-26
US20190117784A1 (en) 2019-04-25
US8440714B2 (en) 2013-05-14
US9889201B2 (en) 2018-02-13
US9339555B2 (en) 2016-05-17
US20160354475A1 (en) 2016-12-08
AU2012275953B2 (en) 2015-01-22
JP5621071B2 (ja) 2014-11-05
US8716328B2 (en) 2014-05-06
CN103763928B (zh) 2016-09-21

Similar Documents

Publication Publication Date Title
MX337464B (es) Profarmacos lipofilicos labiles al acido de los agentes quimioterapeuticos contra el cancer.
MX350539B (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos.
HK1206268A1 (en) Non linear multiblock copolymer drug conjugates for the delivery of active agents
MX361218B (es) Análogos de spliceostatina.
MX356698B (es) Compuestos de tubulisina, metodos para obtenerlos y uso.
NZ705910A (en) Pyrrolobenzodiazepines and conjugates thereof
IN2014DN11099A (es)
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
IN2015KN00005A (es)
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents
RS52880B (en) NANOPARTICLES IN WHICH A CHEMOTHERAPY ANTITUMOR DRUG IS INSERTED
TR201908514T4 (tr) İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
IN2014MN02214A (es)
MX2020014208A (es) Agentes terapeuticos para administracion subcutanea optimizados.
TN2014000322A1 (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
EP4360621A3 (en) Formulations of bendamustine
MX2012014479A (es) Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso.
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
EP2836217A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS
EP2961424A4 (en) ADMINISTRATION OF AN ANTI-GCC-ANTIBODY-ACTIVE CONJUGATE AND A DNA DAMAGING ACTIVE IN THE TREATMENT OF CANCER
MX2016001259A (es) Polisacarido para el uso en la prevencion de la formacion y/o la reincidencia de metastasis.
UA69222U (ru) Способ рефлексотерапии больных с отдаленными последствиями черепно-мозговой травмы
WO2013035053A3 (en) Novel conjugation-facilitated transport of drugs across blood brain barrier

Legal Events

Date Code Title Description
FG Grant or registration